A single-institution study explored the safety and efficacy of brain radiotherapy and concurrent tremelimumab-mediated CTLA-4 blockade with or without trastuzumab for patients with breast cancer brain metastases. The gene discussed is CTLA4; the disease is breast carcinoma.